InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Biosimilar Monoclonal Antibodies Market- by Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab and Other Pipeline Products), Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders and Other Indication), Trends, Industry Competition Analysis, Revenue and Forecast To 2034.”
According to the latest research by InsightAce Analytic, the global Biosimilar Monoclonal Antibodies Market Size is valued at USD 7.8 Billion in 2024 and is predicted to reach USD 32.1 Billion by the year 2034 at a 15.3% CAGR during the forecast period for 2025-2034.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1218
The production of monoclonal antibodies (mAbs) involves the use of identical immune cell clones derived from a single parent cell. As these antibodies originate from the same cell line, they exhibit uniformity in structure and function and are thus classified as biosimilar monoclonal antibodies. These biosimilars fall under the broader category of biotherapeutic products and are developed to be comparable to their reference biologic counterparts in terms of quality, efficacy, and safety.
The rising production of advanced monoclonal antibodies, the rising geriatric population, and the high prevalence of chronic diseases like cancer, kidney failure, rheumatoid arthritis, psoriasis, diabetes, and others are all contributing factors to the growth of the global market for biosimilar monoclonal antibodies. As more mAbs’ patents expire, more chances for market expansion are anticipated over the coming years.
North America is anticipated to be the major contributor to the Biosimilar Monoclonal Antibodies market over the forecast years. The region’s strong growth can be ascribed to increased product approvals, a well-established health care infrastructure, and a favorable reimbursement scenario. In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period because chronic disease burden, the need for affordable therapies, and government funding for healthcare facility improvements are all on the rise.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1218
Major market players operating in the Biosimilar Monoclonal Antibodies market include
BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.
Recent collaborations and agreements in the market:
- In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support third-party biosimilar development. This collaboration resulted in an integrated solution by two prominent service providers in biosimilar development and GMP manufacturing.
- In February 2021, Mylan (US) introduced Ogivri, a trastuzumab biosimilar. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer, previously sold as Herceptin by Genentech.
Get Specific Chapter/Information From The Report: @
https://www.insightaceanalytic.com/customisation/1218
Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Product, 2025-2034 (Value US$ Mn)
- Infliximab
- Trastuzumab
- Rituximab
- Adalimumab
- Bevacizumab
- Cetuximab
- Ranibizumab
- Denosumab
- Eculizumab
- Other Pipeline Products
Global Biosimilar Monoclonal Antibodies Market, by Indication, 2025-2034 (Value US$ Mn)
- Oncology
- Inflammatory & Autoimmune Disorders
- Chronic Diseases
- Blood Disorders
- Other Indication
Global Biosimilar Monoclonal Antibodies Market, by Region, 2025-2034 (Value US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Biosimilar Monoclonal Antibodies Market, by Country, 2025-2034 (Value US$ Mn)
- S.
- Canada
Europe Biosimilar Monoclonal Antibodies Market, by Country, 2025-2034 (Value US$ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2025-2034 (Value US$ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2025-2034 (Value US$ Mn)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2025-2034 (Value US$ Mn)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Get More Information :
https://www.insightaceanalytic.com/report/global-biosimilar-monoclonal-antibodies-market/1218
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
